Old Web
English
Sign In
Acemap
>
Paper
>
Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia
Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia
2021
Andrew Matthews
Alexander E. Perl
Selina M. Luger
Daria V. Babushok
Noelle V. Frey
Saar Gill
Elizabeth O. Hexner
Mary Ellen Martin
Shannon R. McCurdy
David L. Porter
Edward A. Stadtmauer
Alison W. Loren
Vikram R Paralkar
Ivan Maillard
David J. Margolis
Keith W. Pratz
Keywords:
Venetoclax
Oncology
Internal medicine
Medicine
Adult Acute Myeloid Leukemia
initial therapy
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]